Neomycin and Polymyxin B Sulfates
CGMP Deviations:
241 recalls, newest first
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
CGMP Deviations:
Incorrect Product Formulation: Oxytocin 30 units was added to an IV bag of 0.45% Sodium Chloride (500mL) instead of 0.9% Sodium Chloride (500mL).
GMP Deviations: FDA analysis found product to contain acetaldehyde and acetal above specification limits.
CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.
CGMP Deviations: Product complaints reporting the product to have a gritty texture and lack of effectiveness.
CGMP Deviations;
CGMP Deviations
CGMP Deviations
CGMP Deviations
Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection
Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection
Lack of Processing Controls: Insanitary conditions observed during recent FDA Inspection